Per Zauba, India has exported
~997cr of gNexium to US (from Mar 01, 2015 to Nov 12, 2015)
~252cr of gNexium to US (from Oct 21, 2015 to Nov 12, 2015)
Attached file has the related raw data to chew.
Esomeprazole Magnesium v1.xlsx (30.9 KB)
Note: In addition to Torrent and Hetero, the above numbers would include Cipla's gNexium supply to Teva.
Old but interesting article on Amrutanjan v/s Zandu v/s Tiger balms
http://www.business-standard.com/article/management/amrutanjan-pain-for-suitors-110050600008_1.html
UK govt granted approval on October 01, 2015. Pl refer attachment
1 Marketing authorisations granted in October 2015
PL Number Grant Date MA Holder Licensed Name(s) Active Ingredient Quantity Units Legal Status
PL 36687/0142 01/10/2015 TORRENT PHARMA (UK) LIMITED ARIPIPRAZOLE TORRENT 10 MG ORODISPERSIBLE TABLETS ARIPIPRAZOLE 10.000 MILLIGRAMMES POM
PL 36687/0143 01/10/2015 TORRENT PHARMA (UK) LIMITED ARIPIPRAZOLE TORRENT 15 MG ORODISPERSIBLE TABLETS ARIPIPRAZOLE 15.000 MILLIGRAMMES POM
UK Govt Approval to market Abilify
Mahesh,
Thanks. And sorry for the confusion. My mistake
Let's focus and dig deeper on SPS http://www.sps.co.in/, NewGen http://www.newgen.co/, and TNQ http://www.tnq.co.in/
@varadharajanr
Re: contacts in the industry, let's do a call
Hi Donald,
I think you have misunderstood my point....I am not saying that management is saying any lies or something...infact I have been on record in this thread saying that management led by Mr. Nishith Arora has been one of the best and most ethical management I have seen in mid-cap cos.......otherwise MPS would have not formed more than 20 % of my family portfolio......but, some facts are facts that we need to accept.....as I have said in my last post and I repeat that 'severe' pricing pressures (which lead to good volume growth but muted value growth) seem to be absent in reasonable peers....SPS, I told before also, could be beneficiary of its parent....
Rgdg., Newgen, my analysis makes me believe that it is in the similar area as MPS (If I remember correctly, even Mr. Arora has told this in the MPS's initial concalls).....
link that you seem to have provided www.newgensoft.com -- is this the same co. or affiliated co. of Newgen Knowledgeworks ?? I have always referred Newgen Knowledgeworks in which PEs are invested and I believe its website is -- www.newgen.co -- If I am wrong then pardon me but in all the mca filings that I have same website is referred.
TNQ also seem to be a very close l-t-l peer. Its YoY data I have provided before also -- its 9 %, 32 % and 35 % for FY12, 13 and 14 respectively with EBITDA margins of 30.4, 23.3 and 42.3 % respectively.
Also, what I have understood of this industry is that when you say l-t-l you have to see the clients and segments it serves.....for ex., you can't compare a player like Impelsys which is largely a platform play with MPS but otherwise what every player including MPS is eventually attempting is to plug the gaps in its offerings and offer maximum it can offer....In that sense even what Mr. Arora tells of his vision to approach its largest peer Aptara's scale -- even Aptara is present in other segments (XBRL) and serves those end clients (BFSI) which I don't think MPS serves.
To conclude, evenif I see the most closest l-t-l comparable Indian peers like SPS, Newgen or TNQ, I don't find 'severe' pricing pressure that could amount to a single digit organic growth post stabilisation period. This is the only disconnect I can find in story or, specifically speaking, management commentry otherwise the story seems compelling to me personally.
The biggest advantage that I see for MPS in this industry is its positioning.....which is slipping every passing year as its reasonable peers are growing that much faster......I see no point in comparing MPS with small peers which have sub-80 or -50 cr. revenues (in my initial posts I have given all the data points wrt different scale cos. Revenue CAGR and EBITDA margins).....MPS surely is well positioned and its credibility is very high but organic growth has to start somewhere for it to be great wealth creator for all of us.....company's operating matrix is excellent with Mr. Rahul Arora also specifically pointing to his focus on improving margins further in recent concall.....Mr. Nishith Arora -- the great man behind building and divesting ITC at premium rates and then turning around MPS in style has taken the sole responsibility for crucial acquisitions thats also reassuring from investor point-of-view.....but two things we need to understand :
(1) Without Organic Growth story will struggle in long run,
(2) EBITDA margins of 35 % + that we see might settle for 25 or max 30 % range as company scales up (even Newgen at consolidated level seems to be operating at 30-32 % margins).
Rgdg. contacts, I think Varadha has some very good contacts in the industry.
Rgds.
( You can refer my September'2014 post in this thread in which I have given all the data points scalewise of different cos.)
(post withdrawn by author, will be automatically deleted in 24 hours unless flagged)
@ravijain88
Thanks for the prompt reply. I appreciate it!
Any clue on today's rally by Cupid, Anyone!
Health ministry plans to revamp regulatory rules for biosimilar drugs
By Vikas Dandekar, ET Bureau | 18 Nov, 2015, 04.00AM ISTPost a Comment
!
MUMBAI: The health ministry plans to revamp guidelines for approving biosimilar drugs to make the regulatory pathway more robust and sync it with the rapidly evolving global landscape. The guidelines were released three years ago.
Biosimilars are copies of complex drugs, which are based on living cells and 'similar' to an original biologic manufactured by the innovator. These drugs stand distinct from the chemical-based generic drugs that are 'identical' to the originator's compound.
Officials say the new norms are expected to build further on the existing rules. They will be finalised after consultations with the industry, academic institutions and stakeholders like the civil society. "We will put up the draft in public domain and seek views prior to giving a final shape to the new rules," a senior health ministry official said, adding that the ministry aims to finalise the rules by year-end. "A large number of future products will be from biologics origins and it is important to be geared up to examine those filings with clear rules."
The new rules are intended to drill specifically on areas like comparability tests with the reference drug and also address issues such as pharmacovigilance and post-marketing surveillance to report any adverse events.
Health ministry plans to revamp regulatory rules for biosimilar drugs
The existing proposals, called Guidelines on Similar Biologics, were released by the department of biotechnology in 2012. They offer a broad roadmap for lab tests, clinical trials and manufacturing processes. The new norms may set the threshold for the minimum number of patients needed for clinical trials and depending on the drug, the number may be increased. "Some key issues were not specified in the first guidelines, which had created scope for interpretations," an industry executive said.
Biocon chairman Kiran Mazumdar Shaw told ET that the Association of Biotech-led Enterprises (ABLE) is looking forward to the pathway that enables safe and dependable biosimilars. ABLE is the local industry group of biotech players.
Shaw advocated the use of new innovative technologies to ensure patient safety and better treatment outcomes, in line with the efforts followed by drug regulators in developed markets. She said stress should be on establishing a pathway for robust molecular characterization from the initial stages, mitigate risks and assess efficacy to demonstrate non-inferiority of tested compound.
Leading Indian drug makers like Biocon, Dr. Reddy'sBSE -1.89 %, CiplaBSE -0.68 %, Zydus Cadila and Intas are pursuing ambitious programmes to tap the emerging global biosimilars market.
ET View: Focus on Awareness
We need to proceed cautiously. Reportedly, the first biosimilar drug was approved in the US earlier this year. Note, biosimilar drugs are not really perfect copies. It follows that biosimilars are not generic versions of original molecules. Hence, it is vital that prescribers & patients are educated on safety aspect, if need be after trials and tests.
Thanks Mahesh as always for taking the discourse further. And providing answers to the gaps !
Yes, its a good idea to present Competition data points again to MPS Management, at Conference Calls and other interactions with Management consistently. We did raise this in the Mgmt Q&A at a first level - MPS wanted to see if FY15 stellar margins reported by SPS sustains in FY16 - before responding further on this point.
We do not find inconsistency in the Management commentary, atleast not yet. From our perspective these are the counter-arguments to your thesis.
Any others competitors in STM Market with higher margins that you can point to?
Did you cultivate any contacts in the STM Technology Vendor space? We are now primed to extract the most out of any direct interaction with domain specialist folks 
Dear @CommonMan,
Possibility of a cartel has already been discussed in this thread, so such panic is unwarranted.
If you would've read the first 10 posts in this thread, you would've understood that most boarders are here for opportunistic gains with an understanding of risk factors and are not chasing a multibagger blindly.
I know new members like me are not even half good as core VP members but we try to do our bit. The least I expect is that you read our posts before passing judgment.
Regards
